Evoke Pharma Stock Price, News & Analysis (NASDAQ:EVOK)

$2.02 +0.01 (+0.50 %)
(As of 02/23/2018 01:35 AM ET)
Previous Close$2.01
Today's Range$1.94 - $2.05
52-Week Range$1.94 - $4.09
Volume115,900 shs
Average Volume92,703 shs
Market Capitalization$31.14 million
P/E Ratio-2.15
Dividend YieldN/A
Beta1.26

About Evoke Pharma (NASDAQ:EVOK)

Evoke Pharma logoEvoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

Receive EVOK News and Ratings via Email

Sign-up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:EVOK
CUSIPN/A
Phone+1-858-3451494

Debt

Debt-to-Equity RatioN/A
Current Ratio4.07%
Quick Ratio4.07%

Price-To-Earnings

Trailing P/E Ratio-2.14893617021277
Forward P/E Ratio-2.02
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.31 per share
Price / Book6.52

Profitability

Trailing EPS($0.94)
Net Income$-10,740,000.00
Net MarginsN/A
Return on Equity-212.28%
Return on Assets-90.71%

Miscellaneous

Employees7
Outstanding Shares15,410,000

Evoke Pharma (NASDAQ:EVOK) Frequently Asked Questions

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

How were Evoke Pharma's earnings last quarter?

Evoke Pharma Inc (NASDAQ:EVOK) released its quarterly earnings data on Tuesday, November, 14th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.13. During the same quarter last year, the company posted ($0.29) earnings per share. View Evoke Pharma's Earnings History.

When will Evoke Pharma make its next earnings announcement?

Evoke Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, March, 13th 2018. View Earnings Estimates for Evoke Pharma.

Where is Evoke Pharma's stock going? Where will Evoke Pharma's stock price be in 2018?

7 equities research analysts have issued 1 year price objectives for Evoke Pharma's stock. Their predictions range from $6.00 to $10.00. On average, they expect Evoke Pharma's stock price to reach $9.14 in the next year. View Analyst Ratings for Evoke Pharma.

What are Wall Street analysts saying about Evoke Pharma stock?

Here are some recent quotes from research analysts about Evoke Pharma stock:

  • 1. According to Zacks Investment Research, "Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. " (2/6/2018)
  • 2. FBR & Co analysts commented, "Last week, we hosted EVOK’s management, including CEO David Gonyer RPh, along with chief business officer Matthew D’Onofrio, for a conference call with investors. Our call came after EVOK had reported positive results from a comparative PK study with its pipeline drug, Gimoti nasal spray, for treating symptoms of diabetic gastroparesis (delayed stomach emptying not caused by obstruction), versus Reglan. Bottom line: The results showed that two of three doses met targeted bioequivalence ranges, versus Reglan tablets; and EVOK plans to submit its 505 (b) (2) NDA with the FDA during 1Q18. This sets up a potential approval for EVOK’s drug by late 2018/early 2019; we have previously highlighted a peak potential of ~$500M for Gimoti and sales of ~$245M by 2022, with the scenario that EVOK self-markets, building its own sales force, and sees revenue and earnings ramps starting in 2019. Our price target of $10/share reflects a P/E multiple–based target, based upon 2022E earnings power, and a 13.5x multiple, discounted at 15%/year to present value, along with an additional 25% risk discount." (10/30/2017)
  • 3. Northland Securities analysts commented, "We are resuming coverage of Evoke Pharma, Inc. (EVOK) with a Buy rating and a $10 per share price target predicated upon the company being able to (1) show successful results for a PK (pharmacokinetic comparative study in healthy volunteers) study for Gimoti (nasal spray metoclopramide) and (2) successfully file a 505(b)(2) New Drug Application (NDA) by year-end 2017 or early 2018. An investment in EVOK is highly dependent on the success of Gimoti’s PK study and the ability to file this drug with the FDA. We expect Gimoti, if successfully approved, to be a potential $500 million peak sales drug. We see EVOK worth ~ $10 per share based upon potential earnings power of $2.40 per share in 2022. Our valuation represents a risk adjustment of 25%, and valuation is discounted to present at 15%." (10/18/2017)
  • 4. Ascendiant Capital Markets analysts commented, "Maintaining our BUY rating, but raising our 12-month price target to $6 from $5, which is based on an NPV analysis. Though we acknowledge that it is still at an early stage, we believe the large market potential presents a high reward for the risks." (3/16/2017)

Who are some of Evoke Pharma's key competitors?

Who are Evoke Pharma's key executives?

Evoke Pharma's management team includes the folowing people:

  • Cam L. Garner, Chairman and Co Founder (Age 67)
  • David A. Gonyer, CEO, Founder, Director (Age 52)
  • Matthew J. D'Onofrio, Executive Vice President, Chief Business Officer Treasurer, Secretary , (Age 45)
  • Marilyn R. Carlson M.D., Chief Medical Officer (Age 67)
  • Todd C. Brady M.D. Ph.D., Director (Age 46)
  • Scott L. Glenn, Director (Age 61)
  • Ann D. Rhoads, Director (Age 51)
  • Ken Jon Widder M.D., Director (Age 64)

Who owns Evoke Pharma stock?

Evoke Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sphera Funds Management LTD. (4.99%), Deutsche Bank AG (1.30%), 683 Capital Management LLC (0.74%), B. Riley Financial Inc. (0.71%) and Creative Planning (0.65%). Company insiders that own Evoke Pharma stock include Kenneth J Widder and Parters Vii L P Domain. View Institutional Ownership Trends for Evoke Pharma.

Who bought Evoke Pharma stock? Who is buying Evoke Pharma stock?

Evoke Pharma's stock was bought by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Sphera Funds Management LTD., 683 Capital Management LLC, B. Riley Financial Inc. and Creative Planning. View Insider Buying and Selling for Evoke Pharma.

How do I buy Evoke Pharma stock?

Shares of Evoke Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Evoke Pharma's stock price today?

One share of Evoke Pharma stock can currently be purchased for approximately $2.02.

How big of a company is Evoke Pharma?

Evoke Pharma has a market capitalization of $31.14 million. The specialty pharmaceutical company earns $-10,740,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. Evoke Pharma employs 7 workers across the globe.

How can I contact Evoke Pharma?

Evoke Pharma's mailing address is 420 Stevens Ave Ste 370, SOLANA BEACH, CA 92075-2081, United States. The specialty pharmaceutical company can be reached via phone at +1-858-3451494 or via email at [email protected]


MarketBeat Community Rating for Evoke Pharma (EVOK)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  261 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  400
MarketBeat's community ratings are surveys of what our community members think about Evoke Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Evoke Pharma (NASDAQ:EVOK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.882.882.80
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.14$9.00$9.00$8.20
Price Target Upside: 242.43% upside237.08% upside237.08% upside250.43% upside

Evoke Pharma (NASDAQ:EVOK) Consensus Price Target History

Price Target History for Evoke Pharma (NASDAQ:EVOK)

Evoke Pharma (NASDAQ:EVOK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/29/2017HC WainwrightSet Price TargetBuy$9.00MediumView Rating Details
11/15/2017B. RileyReiterated RatingBuy$10.00N/AView Rating Details
10/30/2017FBR & CoReiterated RatingBuy$10.00N/AView Rating Details
10/18/2017Northland SecuritiesReiterated RatingBuy$10.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$10.00N/AView Rating Details
3/16/2017Ascendiant Capital MarketsBoost Price TargetIn-Line$5.00 -> $6.00HighView Rating Details
3/16/2017Rodman & RenshawReiterated RatingBuy -> Buy$6.00 -> $9.00HighView Rating Details
1/30/2017LaidlawUpgradeNeutral -> Buy$8.00N/AView Rating Details
8/16/2016Noble FinancialReiterated RatingHoldN/AView Rating Details
7/18/2016Feltl & Co.DowngradeStrong-Buy -> SellN/AView Rating Details
7/18/2016Brean CapitalDowngradeBuy -> HoldN/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Evoke Pharma (NASDAQ:EVOK) Earnings History and Estimates Chart

Earnings by Quarter for Evoke Pharma (NASDAQ:EVOK)

Evoke Pharma (NASDAQ EVOK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2018($0.23)N/AView Earnings Details
11/14/2017Q3 2017($0.21)($0.34)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.12)($0.27)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.16)($0.14)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.19)($0.12)ViewN/AView Earnings Details
11/9/2016Q316($0.27)($0.29)ViewListenView Earnings Details
8/15/2016Q216($0.43)($0.41)ViewListenView Earnings Details
5/11/2016Q116($0.41)($0.45)ViewListenView Earnings Details
3/10/2016Q415($0.45)($0.37)ViewListenView Earnings Details
11/12/2015Q315($0.56)($0.42)ViewListenView Earnings Details
8/13/2015Q215($0.60)($0.52)ViewListenView Earnings Details
5/14/2015Q115($0.55)($0.58)ViewListenView Earnings Details
3/4/2015Q414($0.80)($0.48)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.78)($0.63)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.73)($0.59)ViewN/AView Earnings Details
5/13/2014Q114($0.38)($0.49)ViewN/AView Earnings Details
3/25/2014Q413($0.16)($0.27)ViewN/AView Earnings Details
11/13/2013Q3 13($0.10)($0.41)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Evoke Pharma (NASDAQ:EVOK) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.10)($0.10)($0.10)
Q3 20181($0.09)($0.09)($0.09)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Evoke Pharma (NASDAQ:EVOK)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Evoke Pharma (NASDAQ EVOK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 20.00%
Institutional Ownership Percentage: 16.50%
Insider Trades by Quarter for Evoke Pharma (NASDAQ:EVOK)
Institutional Ownership by Quarter for Evoke Pharma (NASDAQ:EVOK)

Evoke Pharma (NASDAQ EVOK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/22/2017Kenneth J WidderDirectorBuy450,000$2.90$1,305,000.00View SEC Filing  
5/26/2016Parters Vii L P DomainMajor ShareholderSell344,120$4.70$1,617,364.00View SEC Filing  
4/27/2016Parters Vii L P DomainMajor ShareholderSell5,095$5.07$25,831.65View SEC Filing  
4/25/2016Parters Vii L P DomainMajor ShareholderSell1,492$5.20$7,758.40View SEC Filing  
4/20/2016Parters Vii L P DomainMajor ShareholderSell41,478$5.35$221,907.30View SEC Filing  
4/11/2016Parters Vii L P DomainMajor ShareholderSell4,348$5.22$22,696.56View SEC Filing  
4/8/2016Parters Vii L P DomainMajor ShareholderSell51,004$5.28$269,301.12View SEC Filing  
8/18/2015Parters Vii L P DomainMajor ShareholderSell11,836$7.02$83,088.72View SEC Filing  
4/16/2015Parters Vii L P DomainMajor ShareholderSell50,163$7.29$365,688.27View SEC Filing  
9/23/2014Todd C BradyDirectorBuy4,000$5.70$22,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Evoke Pharma (NASDAQ EVOK) News Headlines

Source:
DateHeadline
Contrasting Akorn (AKRX) & Evoke Pharma (EVOK)Contrasting Akorn (AKRX) & Evoke Pharma (EVOK)
www.americanbankingnews.com - February 22 at 3:48 PM
Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2017 Financial ResultsEvoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - February 21 at 8:50 AM
EVOKE PHARMA, INC. - StreetInsider.comEVOKE PHARMA, INC. - StreetInsider.com
www.streetinsider.com - February 15 at 8:13 AM
Evoke Announces Discovery of Sex-Based Pharmacokinetic Differences for Gimoti™Evoke Announces Discovery of Sex-Based Pharmacokinetic Differences for Gimoti™
finance.yahoo.com - February 15 at 8:13 AM
Evoke Pharma Inc (EVOK) Expected to Announce Earnings of -$0.22 Per ShareEvoke Pharma Inc (EVOK) Expected to Announce Earnings of -$0.22 Per Share
www.americanbankingnews.com - February 14 at 3:10 PM
Evoke Pharma Inc (EVOK) Given Average Recommendation of "Buy" by AnalystsEvoke Pharma Inc (EVOK) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 13 at 7:30 PM
Evoke Pharma (EVOK) Raised to Hold at Zacks Investment ResearchEvoke Pharma (EVOK) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - February 6 at 11:06 PM
Evoke Pharma (EVOK) Upgraded to "Hold" by Zacks Investment ResearchEvoke Pharma (EVOK) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - January 31 at 11:58 PM
Zacks: Analysts Expect Evoke Pharma Inc (EVOK) Will Announce Earnings of -$0.22 Per ShareZacks: Analysts Expect Evoke Pharma Inc (EVOK) Will Announce Earnings of -$0.22 Per Share
www.americanbankingnews.com - January 28 at 5:12 PM
Evoke Pharma Inc (EVOK) Receives Average Rating of "Buy" from AnalystsEvoke Pharma Inc (EVOK) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - January 19 at 9:52 PM
 Analysts Anticipate Evoke Pharma Inc (EVOK) to Announce -$0.22 EPS Analysts Anticipate Evoke Pharma Inc (EVOK) to Announce -$0.22 EPS
www.americanbankingnews.com - December 26 at 5:46 AM
Evoke Pharma Inc (EVOK) Given Consensus Recommendation of "Buy" by AnalystsEvoke Pharma Inc (EVOK) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 25 at 7:54 PM
Head to Head Review: Sagent Pharmaceuticals (SGNT) and Evoke Pharma (EVOK)Head to Head Review: Sagent Pharmaceuticals (SGNT) and Evoke Pharma (EVOK)
www.americanbankingnews.com - December 15 at 11:16 PM
Wired News – Akari’s Phase-II COBALT Trial of Coversin in Patients with PNH Met the Primary EndpointWired News – Akari’s Phase-II COBALT Trial of Coversin in Patients with PNH Met the Primary Endpoint
finance.yahoo.com - December 12 at 10:05 AM
Wired News – SteadyMed Reported FDA Agreed Pathway to Trevyent NDA ResubmissionWired News – SteadyMed Reported FDA Agreed Pathway to Trevyent NDA Resubmission
finance.yahoo.com - December 11 at 10:24 AM
 Brokerages Anticipate Evoke Pharma Inc (EVOK) Will Announce Earnings of -$0.22 Per Share Brokerages Anticipate Evoke Pharma Inc (EVOK) Will Announce Earnings of -$0.22 Per Share
www.americanbankingnews.com - December 8 at 3:30 PM
Evoke Pharma (EVOK) Downgraded by ValuEngine to Strong SellEvoke Pharma (EVOK) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - December 3 at 3:12 PM
Zacks Investment Research Lowers Evoke Pharma (EVOK) to SellZacks Investment Research Lowers Evoke Pharma (EVOK) to Sell
www.americanbankingnews.com - December 1 at 9:54 PM
Evoke Pharma, Inc. (EVOK) Receives Average Recommendation of "Buy" from AnalystsEvoke Pharma, Inc. (EVOK) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 30 at 9:56 PM
Evoke Pharma (EVOK) PT Set at $9.00 by HC WainwrightEvoke Pharma (EVOK) PT Set at $9.00 by HC Wainwright
www.americanbankingnews.com - November 29 at 1:00 PM
Apricus Biosciences (APRI) versus Evoke Pharma (EVOK) Head-To-Head ReviewApricus Biosciences (APRI) versus Evoke Pharma (EVOK) Head-To-Head Review
www.americanbankingnews.com - November 23 at 9:36 PM
Evoke Pharma, Inc. (EVOK) Upgraded to "Hold" at Zacks Investment ResearchEvoke Pharma, Inc. (EVOK) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - November 20 at 10:52 PM
Evoke Pharma, Inc. (EVOK) Expected to Announce Earnings of -$0.20 Per ShareEvoke Pharma, Inc. (EVOK) Expected to Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - November 20 at 3:18 PM
Evoke Pharma, Inc. Forecasted to Earn Q4 2017 Earnings of ($0.26) Per Share (EVOK)Evoke Pharma, Inc. Forecasted to Earn Q4 2017 Earnings of ($0.26) Per Share (EVOK)
www.americanbankingnews.com - November 17 at 10:40 PM
A Look At Evoke Pharma Inc (EVOK) And The Healthcare Sector - Yahoo NewsA Look At Evoke Pharma Inc (EVOK) And The Healthcare Sector - Yahoo News
finance.yahoo.com - November 16 at 2:05 PM
Evoke Pharma, Inc. (EVOK) Rating Reiterated by B. RileyEvoke Pharma, Inc. (EVOK) Rating Reiterated by B. Riley
www.americanbankingnews.com - November 16 at 1:28 PM
Evoke Pharma, Inc. (EVOK) Issues  Earnings ResultsEvoke Pharma, Inc. (EVOK) Issues Earnings Results
www.americanbankingnews.com - November 15 at 1:13 PM
Evoke Pharma Reports Third Quarter 2017 Results and Highlights - GlobeNewswire (press release)Evoke Pharma Reports Third Quarter 2017 Results and Highlights - GlobeNewswire (press release)
globenewswire.com - November 14 at 11:54 PM
A Look At Evoke Pharma Inc (EVOK) And The Healthcare SectorA Look At Evoke Pharma Inc (EVOK) And The Healthcare Sector
finance.yahoo.com - November 14 at 6:53 PM
Evoke Pharma, Inc. to Host Earnings CallEvoke Pharma, Inc. to Host Earnings Call
finance.yahoo.com - November 14 at 6:53 PM
Evoke Pharma Reports Third Quarter 2017 Results and HighlightsEvoke Pharma Reports Third Quarter 2017 Results and Highlights
finance.yahoo.com - November 14 at 6:53 PM
Evoke Pharma Signs Commercial Agreement with Thermo Fisher ScientificEvoke Pharma Signs Commercial Agreement with Thermo Fisher Scientific
finance.yahoo.com - November 10 at 2:20 PM
Critical Contrast: Evoke Pharma (EVOK) vs. Amicus Therapeutics (FOLD)Critical Contrast: Evoke Pharma (EVOK) vs. Amicus Therapeutics (FOLD)
www.americanbankingnews.com - November 8 at 9:32 PM
Evoke Pharma Schedules Conference Call and Webcast for Third Quarter 2017 Financial Results - GlobeNewswire (press release)Evoke Pharma Schedules Conference Call and Webcast for Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 8 at 6:42 AM
Is It The Right Time To Buy Evoke Pharma Inc (EVOK)?Is It The Right Time To Buy Evoke Pharma Inc (EVOK)?
finance.yahoo.com - November 8 at 6:42 AM
Evoke Pharma Schedules Conference Call and Webcast for Third Quarter 2017 Financial ResultsEvoke Pharma Schedules Conference Call and Webcast for Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 6:42 AM
Evoke Pharma, Inc. (EVOK) Receives Consensus Recommendation of "Buy" from BrokeragesEvoke Pharma, Inc. (EVOK) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 5 at 7:16 PM
Head-To-Head Contrast: Evoke Pharma (EVOK) versus The CompetitionHead-To-Head Contrast: Evoke Pharma (EVOK) versus The Competition
www.americanbankingnews.com - October 31 at 3:07 PM
Evoke Pharma, Inc. (EVOK) Scheduled to Post Earnings on TuesdayEvoke Pharma, Inc. (EVOK) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:11 AM
Evoke Pharma, Inc. (EVOK) Rating Reiterated by FBR & CoEvoke Pharma, Inc. (EVOK) Rating Reiterated by FBR & Co
www.americanbankingnews.com - October 30 at 8:22 AM
Evoke Pharma (EVOK) & Its Competitors Head to Head ReviewEvoke Pharma (EVOK) & Its Competitors Head to Head Review
www.americanbankingnews.com - October 28 at 1:30 AM
Evoke Pharma Announces Conference Call to Review the Successful Results of Comparative Exposure ... - GlobeNewswire (press release)Evoke Pharma Announces Conference Call to Review the Successful Results of Comparative Exposure ... - GlobeNewswire (press release)
globenewswire.com - October 27 at 3:43 PM
Evoke Pharma Announces Conference Call to Review the Successful Results of Comparative Exposure Pharmacokinetic Study for Gimoti™Evoke Pharma Announces Conference Call to Review the Successful Results of Comparative Exposure Pharmacokinetic Study for Gimoti™
finance.yahoo.com - October 27 at 3:43 PM
Critical Comparison: CoLucid Pharmaceuticals (CLCD) & Evoke Pharma (EVOK)Critical Comparison: CoLucid Pharmaceuticals (CLCD) & Evoke Pharma (EVOK)
www.americanbankingnews.com - October 26 at 7:58 AM
Evoke Pharma, Inc. to Post FY2020 Earnings of $1.10 Per Share, FBR & Co Forecasts (EVOK)Evoke Pharma, Inc. to Post FY2020 Earnings of $1.10 Per Share, FBR & Co Forecasts (EVOK)
www.americanbankingnews.com - October 25 at 7:34 PM
Evoke Pharma Announces Positive Topline Results from Comparative Exposure Pharmacokinetic Study for Gimoti™ - GlobeNewswire (press release)Evoke Pharma Announces Positive Topline Results from Comparative Exposure Pharmacokinetic Study for Gimoti™ - GlobeNewswire (press release)
globenewswire.com - October 24 at 11:16 PM
Evoke Pharma (EVOK) Reports Positive Topline Results from Comparative Exposure Pharmacokinetic Study for GimotiEvoke Pharma (EVOK) Reports Positive Topline Results from Comparative Exposure Pharmacokinetic Study for Gimoti
www.streetinsider.com - October 23 at 4:13 PM
Evoke Down on "Positive" Topline ResultsEvoke Down on "Positive" Topline Results
www.baystreet.ca - October 23 at 4:13 PM
Evoke Pharma Announces Positive Topline Results from Comparative Exposure Pharmacokinetic Study for Gimoti™Evoke Pharma Announces Positive Topline Results from Comparative Exposure Pharmacokinetic Study for Gimoti™
finance.yahoo.com - October 23 at 4:13 PM
Evoke Pharma, Inc. (EVOK) Forecasted to Earn FY2017 Earnings of ($0.65) Per ShareEvoke Pharma, Inc. (EVOK) Forecasted to Earn FY2017 Earnings of ($0.65) Per Share
www.americanbankingnews.com - October 23 at 3:48 AM

SEC Filings

Evoke Pharma (NASDAQ:EVOK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Evoke Pharma (NASDAQ:EVOK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Evoke Pharma (NASDAQ EVOK) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.